Morris, TP;
(2017)
The effect of biological heterogeneity on R-CHOP treatment outcome in diffuse large B-cell lymphoma across five international regions.
Leukemia and Lymphoma
, 58
(5)
pp. 1178-1183.
10.1080/10428194.2016.1231308.
Preview |
Text
morris_10.108010428194.2016.1231308_accepted.pdf Download (329kB) | Preview |
Abstract
Addressing the global burden of cancer, understanding its diverse biology, and promoting appropriate prevention and treatment strategies around the world has become a priority for the United Nations and International Atomic Energy Agency (IAEA), the WHO, and International Agency for Research on Cancer (IARC). The IAEA sponsored an international prospective cohort study to better understand biology, treatment response, and outcomes of diffuse large B-cell lymphoma (DLBCL) in low and middle-income countries across five UN-defined geographical regions. We report an analysis of biological variation in DLBCL across seven ethnic and environmentally diverse populations. In this cohort of 136 patients treated to a common protocol, we demonstrate significant biological differences between countries, characterized by a validated prognostic gene expression score (p < .0001), but International Prognostic Index (IPI)-adjusted survivals in all participating countries were similar. We conclude that DLBCL treatment outcomes in these populations can be benchmarked to international standards, despite biological heterogeneity.
Type: | Article |
---|---|
Title: | The effect of biological heterogeneity on R-CHOP treatment outcome in diffuse large B-cell lymphoma across five international regions |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1080/10428194.2016.1231308 |
Publisher version: | http://doi.org/10.1080/10428194.2016.1231308 |
Language: | English |
Additional information: | © 2016 Informa UK Limited, trading as Taylor & Francis Group. This is an Accepted Manuscript of an article published by Taylor & Francis in Leukemia & Lymphoma on 10 October 2016, available online: http://www.tandfonline.com/10.1080/10428194.2016.1231308 |
Keywords: | DLBCL, gene expression, risk stratification, prognosis |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL |
URI: | https://discovery-pp.ucl.ac.uk/id/eprint/1520888 |
Archive Staff Only
View Item |